Researchers from the University of Florida have developed a novel mRNA cancer vaccine that aims to reprogram the immune system to target and attack cancer cells effectively. The study led by Elias Sayour reported a new mRNA vaccine design where the mRNA payload was wrapped into a multilamellar vesicle within an onion-like hierarchical structure. The findings were published in the May 9, 2024 issue of Cell.

Researchers from Indiana University presented data from a study that aimed to assess the therapeutic potential of interleukin-9 (IL-9) blockade in the context of lung cancer.

α-Fetoprotein (AFP) is a tumor-associated antigen and an ideal target for T-cell receptor T-cell (TCR-T) therapy. While the safety of AFP-targeting TCR-T products has been previously demonstrated in early clinical trials, the efficacy of these cell therapies is still modest, warranting further research.

Researchers from Gempharmatech Co. Ltd. presented a new humanized mouse model for preclinical research into the functionality and therapeutic potential of IL-12.

Bioatla Inc. has received FDA clearance of its IND application for BA-3361, a conditionally active biologic (CAB)-Nectin-4 antibody-drug conjugate (ADC) for the treatment of multiple tumor types.

Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.

Researchers from Egle Therapeutics SAS presented the discovery of a novel immunocytokine, EGL-001, designed to selectively target tumor-infiltrating regulatory T cells (Tregs).

Context Therapeutics Inc. has received FDA clearance of its IND application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.